Vanguard Group Inc. Has $73.35 Million Position in Loxo Oncology, Inc. (LOXO)

Vanguard Group Inc. increased its position in Loxo Oncology, Inc. (NASDAQ:LOXO) by 24.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 914,719 shares of the biopharmaceutical company’s stock after purchasing an additional 181,471 shares during the period. Vanguard Group Inc. owned approximately 3.50% of Loxo Oncology worth $73,351,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in Loxo Oncology by 8.4% in the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 284 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Loxo Oncology by 3.8% during the 2nd quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock valued at $1,291,000 after acquiring an additional 592 shares during the period. Alps Advisors Inc. lifted its stake in Loxo Oncology by 7.4% during the 2nd quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock valued at $1,893,000 after acquiring an additional 1,623 shares during the period. ProShare Advisors LLC lifted its stake in Loxo Oncology by 13.2% during the 2nd quarter. ProShare Advisors LLC now owns 15,192 shares of the biopharmaceutical company’s stock valued at $1,218,000 after acquiring an additional 1,767 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Loxo Oncology by 4.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,178 shares of the biopharmaceutical company’s stock valued at $1,860,000 after acquiring an additional 2,045 shares during the period.

In related news, CEO Joshua H. Bilenker sold 7,500 shares of Loxo Oncology stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $89.25, for a total transaction of $669,375.00. Following the completion of the sale, the chief executive officer now owns 196,207 shares of the company’s stock, valued at $17,511,474.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Avi Z. Naider sold 5,000 shares of Loxo Oncology stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $90.00, for a total value of $450,000.00. Following the sale, the director now directly owns 144,118 shares of the company’s stock, valued at approximately $12,970,620. The disclosure for this sale can be found here. Insiders have sold 89,896 shares of company stock valued at $7,315,562 in the last ninety days. Corporate insiders own 27.80% of the company’s stock.

Several equities analysts have issued reports on LOXO shares. Morgan Stanley restated an “overweight” rating and set a $103.00 target price (up previously from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $71.00 target price on shares of Loxo Oncology in a research note on Thursday, August 3rd. BTIG Research restated a “buy” rating and set a $102.00 target price (up previously from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Finally, Citigroup Inc. restated a “buy” rating and set a $112.00 target price (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Loxo Oncology currently has an average rating of “Buy” and an average target price of $80.02.

WARNING: “Vanguard Group Inc. Has $73.35 Million Position in Loxo Oncology, Inc. (LOXO)” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/10/31/vanguard-group-inc-has-73-35-million-position-in-loxo-oncology-inc-loxo.html.

Shares of Loxo Oncology, Inc. (NASDAQ LOXO) opened at 87.48 on Tuesday. Loxo Oncology, Inc. has a 52-week low of $17.14 and a 52-week high of $95.92. The stock’s market cap is $2.61 billion. The stock’s 50 day moving average is $87.53 and its 200 day moving average is $71.24.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). During the same period in the previous year, the business earned ($0.77) earnings per share. On average, equities analysts predict that Loxo Oncology, Inc. will post ($4.39) EPS for the current fiscal year.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit